Varilrix offers 3 Reasons for
Reassurance in Varicella Vaccination

How to Prescribe Varilrix

Access product information and Varilrix indication & dosage and administration

Safety Profile

Access information about the safety profile of Varilrix

Disease Information

Find out more information about Varicella and its conditions

Patient Support

Discover helpful resources for your patients

*The original formulation was heat sensitive, requiring storage at -20°C, and was approved for use in high-risk groups and their healthy close contacts4
Infants and children aged from 12 months as well as adolescents and adults should receive two doses of Varilrix. The age at which infants or children may receive Varilrix should reflect applicable official recommendations, which vary depending on the regional epidemiology of varicella4
**The reconstituted vaccine can be kept for a maximum of 90 minutes at room temperature (25°C) or stored in the refrigerator (2–8°C) for a maximum of 8 hours. If the reconstituted vaccine is not used within this time, it must be discarded. Varilrix contains no microbial agent.4

References:

  1.  GlaxoSmithKline (2016) DoF2014N207822_02: Number of Doses Priorix-Tetra Distributed Worldwide (as of Feb 29 2016). [Data on File].
  2. GlaxoSmithKline (2016) DoF2014N207819_02: Number of countries with marketing authorisation for Priorix, Varilrix and Priorix-Tetra (as of Mar 25 2016). [Data on File].
  3. Kreth HW et al. Sixteen years of global experience with the first refrigerator-stable varicella vaccine (Varilrix). BioDrugs 2008; 22(6):387–402.
  4. GlaxoSmithKline. Varilrix Belgian Summary of Product Characteristics. August 2015.
  5. Spackova M et al. Comparative varicella vaccine effectiveness during outbreaks in day-care centres. Vaccine 2010; 28(3):686–691.
  6. Heywood AE et al. Varicella and herpes zoster hospitalizations before and after implementation of one-dose varicella vaccination in Australia: an ecological study. Bull World Health Organ 2014; 92(8):593–604.

AB: Last updated May 2017: MLT_GIB/VAR/0001/17